ProfileGDS5678 / 1441204_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 41% 40% 48% 39% 46% 41% 53% 41% 39% 40% 40% 39% 43% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.975741
GSM967853U87-EV human glioblastoma xenograft - Control 22.915940
GSM967854U87-EV human glioblastoma xenograft - Control 33.126148
GSM967855U87-EV human glioblastoma xenograft - Control 42.8336839
GSM967856U87-EV human glioblastoma xenograft - Control 53.0374246
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0391141
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3761453
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9301241
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8629339
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8989940
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9095340
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8692939
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9974443
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9007739